Maison » Blockbuster Drug Model

Blockbuster Drug Model

1980
Pharmaceutical research laboratory focused on blockbuster drug development.

A “blockbuster drug” is a pharmaceutical product that generates more than $1 billion in annual sales for its manufacturer. This business model has historically driven the pharmaceutical industry, focusing research and development (R&D) on common, chronic conditions to maximize patent-protected revenue. This revenue funds further R&D for new drugs, creating a cycle of innovation and high profits.

The blockbuster model became the dominant strategy for large pharmaceutical companies in the late 20th century. The model relies on developing and patenting a drug that can treat a widespread chronic condition, such as high cholesterol (e.g., Lipitor), acid reflux (e.g., Prilosec), or depression (e.g., Prozac). Once approved, the company launches a massive commercialisation campaign aimed at both physicians and consumers (in countries where direct-to-consumer advertising is legal). The goal is to achieve widespread prescription and capture a large market share. The drug’s brevet provides a period of market exclusivity, typically 20 years from the filing date, during which the company can charge high prices without competition from generic versions. The enormous profits generated during this period are used to recoup the substantial R&D investment—often exceeding $1 billion per approved drug—and to fund the development of the next generation of potential blockbusters. However, this model faces significant challenges. The “low-hanging fruit” of common diseases has largely been addressed, making new discoveries more difficult. Increased pressure from payers (governments and insurance companies) to control costs, and the looming “patent cliff” (when patents for multiple blockbuster drugs expire around the same time), have forced the industry to reconsider this strategy. Many companies are now shifting towards developing more specialized, high-value drugs for smaller patient populations, such as orphan drugs for rare diseases or personalized cancer therapies, which can command even higher prices per patient.

UNESCO Nomenclature: 5312
– Economics of technological change

Type

Abstract System

Disruption

Incremental

Utilisation

Widespread Use

Precursors

  • the bayh-dole act (1980) in the us, which encouraged commercialization of university research
  • le hatch-waxman act (1984), which established the modern system of patent extensions and generic drug approvals
  • advances in molecular biology that enabled rational drug design for common disease targets
  • growth of managed care and large-scale insurance payers

Applications

  • business strategy for major pharmaceutical companies (big pharma)
  • funding mechanism for large-scale r&d programs
  • marketing and sales strategies targeting large patient populations
  • justification for high drug prices during patent life

Brevets :

QUE

Potential Innovations Ideas

!niveaux !!! Adhésion obligatoire

Vous devez être membre de l'association pour accéder à ce contenu.

S’inscrire maintenant

Vous êtes déjà membre ? Connectez-vous ici
Related to: blockbuster drug, pharmaceutical economics, big pharma, patent cliff, drug prices, r&d, marketing, lipitor, la propriété intellectuelle, generic drugs.

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

DISPONIBLE POUR DE NOUVEAUX DÉFIS
Mechanical Engineer, Project, Process Engineering or R&D Manager
Développement de produits efficace

Disponible pour un nouveau défi dans un court délai.
Contactez-moi sur LinkedIn
Plastic metal electronics integration, Design-to-cost, GMP, Ergonomics, Medium to high-volume devices & consumables, Lean Manufacturing, Regulated industries, CE & FDA, CAD, Solidworks, Lean Sigma Black Belt, medical ISO 13485

Nous recherchons un nouveau sponsor

 

Votre entreprise ou institution est dans le domaine de la technique, de la science ou de la recherche ?
> envoyez-nous un message <

Recevez tous les nouveaux articles
Gratuit, pas de spam, email non distribué ni revendu

ou vous pouvez obtenir votre adhésion complète - gratuitement - pour accéder à tout le contenu restreint >ici<

Historical Context

(if date is unknown or not relevant, e.g. "fluid mechanics", a rounded estimation of its notable emergence is provided)

Related Invention, Innovation & Technical Principles

Retour en haut

Vous aimerez peut-être aussi